Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
Ralf Reilmann(George Huntington Institute), Hope Heller(Georgetown University), Douglas R. Langbehn(University of Iowa), Stephanie Gallehawk, Ferdinando Squitieri(Casa Sollievo della Sofferenza), Allison Coleman(University of British Columbia), Stefan Bohlen, Phyllis Chua, Nicholas J. Gross(St. Francis Hospital), Juha‐Matti Savola(Teva Pharmaceuticals (Switzerland)), Karl Kieburtz(Beth Israel Deaconess Medical Center), Kevin Biglan(Eli Lilly (United States)), Carey Gonzales, Rebecca Cousins, Anna Teige Wickenberg(Teva Pharmaceuticals (Israel)), Spyros Papapetropoulos(Massachusetts General Hospital), Beth Borowsky(Teva Pharmaceuticals (United States)), Michael R. Hayden(University of British Columbia), Giuseppe De Michele(University of Naples Federico II), Markus Beuth, Anne‐Catherine Bachoud‐Lévi(Inserm), Igor D. Grachev(Teva Pharmaceuticals (United States)), Andrew McGarry(Cooper Medical School of Rowan University), G. Bernhard Landwehrmeyer(Universität Ulm), J.P. Azulay, Fabienne Calvas, Eli Eyal(Teva Pharmaceuticals (Israel)), Roger A. Barker(University of Cambridge), Raphael M. Bonelli, Pinky Agarwal, Jill Davison, Andrew Feigin(Georgetown University), Karen E. Anderson(Georgetown University), Robin Schubert(George Huntington Institute), Stéphanie Blin, Agnieszka Bebak, Simona Castagliuolo, Laura Dornhege, Beatrix Heim, David Craufurd(Manchester Academic Health Science Centre), Terrence Chong, Jane Griffith, Sue Caldwell, Jonielyn Carlos, Mark Guttman(Georgetown University), А.В. Густов, Pascale Gauteul, E Decorte, Jody Corey‐Bloom(University of California San Diego)
Cited by 108
Related Papers
Huntington disease
|Nature Reviews Disease Primers|2015|1.6k
Mutations in HFE2 cause iron overload in chromosome 1q–linked juvenile hemochromatosis
|Nature Genetics|2003|976
Cells of the human intestinal tract mapped across space and time
|Nature|2021|712